Genelux Announces Promising Data From Two Phase I Trials of GL-ONC1 in Head & Neck Cancer and Mesothelioma
May 27, 2015 08:00 ET
|
Genelux Corporation
Data Demonstrate Favorable Safety Profile and Anti-Tumor Activity
Results to be Presented at ASCO Annual Meeting 2015 During Two Poster Presentations
SAN DIEGO, May 27, 2015 (GLOBE NEWSWIRE) --...
Genelux to Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 at ASCO Annual Meeting 2015
May 12, 2015 08:00 ET
|
Genelux Corporation
SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) -- Genelux Corporation, a clinical-stage biopharmaceutical company focused on the development of vaccinia virus for oncolytic immunotherapy, today announced...